United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2000_register
executive
2010-09-24
article
Government-Owned Invention Available for Licensing
Notices
D09002ee1bdfaf196
D09002ee1bdfaf20b
United States
Department of Defense
originator
org
United States Government Agency or Subagency
United States
Department of the Navy
originator
org
United States Government Agency or Subagency
The Department of the Navy hereby gives notice of the general availability of exclusive or partially exclusive licenses under the following pending patent. Any license granted shall comply with 35 U.S.C. 209 and 37 CFR part 404. Applications will be evaluated utilizing the following criteria: (1) Ability to manufacture and market the technology; (2) manufacturing and marketing ability; (3) time required to bring technology to market and production rate; (4) royalties; (5) technical capabilities; and (6) small business status. Serial No. 94/39011 entitled ``A Recombinant Polypeptide For Use in the Manufacture of Vaccines Against Campylobacter-induced Diarrhea and to Reduce Colonization'' by Lee, Guerry, Berg and Trust filed 15 July 1997. This technology represents an effective vaccine and treatment against Campylobacter diarrhea and comprises a recombinant fusion protein of the maltose binding protein (MBP) of E.coli fused to amino acids 5-337 of the FlaA flagellin of Campylobacter coli VC167. This fusion protein has provided evidence of immunogenicity and protective efficacy against challenge by a heterologous strain of Campylobacter jejuni 81-176 in mammals. The technology avoids the technical problem of inducing the autoimmune Guillain Barre Syndrome (GBS), a post- infection polyneuropathy caused by Campylobacter molecular mimicry of human gangliosides. The technology includes a recombinant DNA construct encoding the immunodominant region of flagellin conserved across the Campylobacter species; expression--systems; methods for inducing an immune response through injectable, intranasal, and oral formulations; and a method for reducing Campylobacter intestinal colonization.
65 FR 15898
https://www.govinfo.gov/app/details/FR-2000-03-24/00-7319
00-7319
fr24mr00-47
3810-FF-P
https://www.govinfo.gov/app/details/FR-2000-03-24/00-7319
https://www.govinfo.gov/content/pkg/FR-2000-03-24/html/00-7319.htm
https://www.govinfo.gov/content/pkg/FR-2000-03-24/pdf/00-7319.pdf
2 p.
15898
15899
65 FR 15898
Government-Owned Invention Available for Licensing; Federal Register Vol. 65, Issue
NOTICE
00-7319
DEPARTMENT OF DEFENSE
Department of the Navy
3810-FF-P
00-7319
Notice.
The Department of the Navy hereby gives notice of the general availability of exclusive or partially exclusive licenses under the following pending patent. Any license granted shall comply with 35 U.S.C. 209 and 37 CFR part 404. Applications will be evaluated utilizing the following criteria: (1) Ability to manufacture and market the technology; (2) manufacturing and marketing ability; (3) time required to bring technology to market and production rate; (4) royalties; (5) technical capabilities; and (6) small business status. Serial No. 94/39011 entitled ``A Recombinant Polypeptide For Use in the Manufacture of Vaccines Against Campylobacter-induced Diarrhea and to Reduce Colonization'' by Lee, Guerry, Berg and Trust filed 15 July 1997. This technology represents an effective vaccine and treatment against Campylobacter diarrhea and comprises a recombinant fusion protein of the maltose binding protein (MBP) of E.coli fused to amino acids 5-337 of the FlaA flagellin of Campylobacter coli VC167. This fusion protein has provided evidence of immunogenicity and protective efficacy against challenge by a heterologous strain of Campylobacter jejuni 81-176 in mammals. The technology avoids the technical problem of inducing the autoimmune Guillain Barre Syndrome (GBS), a post- infection polyneuropathy caused by Campylobacter molecular mimicry of human gangliosides. The technology includes a recombinant DNA construct encoding the immunodominant region of flagellin conserved across the Campylobacter species; expression--systems; methods for inducing an immune response through injectable, intranasal, and oral formulations; and a method for reducing Campylobacter intestinal colonization.
Applications for an exclusive or partially exclusive license may be submitted at any time from the date of this notice.
CDR Charles J. Schlagel, Office of Technology Transfer, NMRC, phone (301) 319-7427, fax (301) 319-7432, e- mail schlagelc@nmripo.nmri.nnmc.navy.mil.
schlagelc@nmripo.nmri.nnmc.navy.mil
Federal Register
Vol. 65, no. 58
Office of the Federal Register, National Archives and Records Administration
2000-03-24
continuing
daily
deposited
born digital
299 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2000-03-24
P0b002ee180a009d6
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr24mr00
https://www.govinfo.gov/app/details/FR-2000-03-24
https://www.govinfo.gov/content/pkg/FR-2000-03-24/pdf/FR-2000-03-24.pdf
https://www.govinfo.gov/content/pkg/FR-2000-03-24/xml/FR-2000-03-24.xml
fdlp
15823
16116
DGPO
2010-09-24
2023-05-05
FR-2000-03-24
machine generated
eng
FR
FR-2000-03-24
65
58